MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-11-2026
Bristol-Myers Squibb Company DIO Ratio 2011-2026 | BMY
Annual DIO Ratio Bristol-Myers Squibb Company
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 68.7 | 68.2 | 85.4 | 79.8 | 76.5 | 98.7 | 194 | 66.6 | 70.2 | 91.6 | 114 | 145 | 118 | 131 | 90.2 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 194 | 66.6 | 99.9 |
Quarterly DIO Ratio Bristol-Myers Squibb Company
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 73.1 | 90.2 | 98.9 | 84.7 | 84.4 | 87.4 | 78.8 | 87.9 | - | 40.2 | 35.3 | 77.5 | - | 85.6 | 76.1 | 64.7 | - | 75.6 | 70.1 | 79.3 | - | 219 | 199 | 137 | - | 66.2 | 67.1 | 68 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 219 | 35.3 | 89 |
DIO Ratio of other stocks in the Biotechnology industry
| Issuer | DIO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
512 | - | - | $ 40.3 B |  USA |
 |
BeiGene, Ltd.
BGNE
|
304 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
bluebird bio
BLUE
|
125 | - | - | $ 546 M | USA |
 |
Midatech Pharma plc
MTP
|
40.6 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Amphastar Pharmaceuticals
AMPH
|
166 | $ 21.38 | 0.09 % | $ 999 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
275 | - | - | - |  Russia |
 |
Aeterna Zentaris
AEZS
|
55.6 | - | 5.93 % | $ 314 M |  Canada |
 |
Akebia Therapeutics
AKBA
|
147 | $ 1.54 | 4.76 % | $ 396 M | USA |
 |
Aquestive Therapeutics
AQST
|
120 | $ 4.16 | -0.84 % | $ 445 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
185 | $ 25.13 | 4.19 % | $ 3.2 B | USA |
 |
Autolus Therapeutics plc
AUTL
|
70.7 | $ 1.49 | 1.36 % | $ 397 M | Britain |
 |
AstraZeneca PLC
AZN
|
206 | - | - | $ 96.9 B | Britain |
 |
CTI BioPharma Corp.
CTIC
|
38.1 | - | - | $ 1.2 B | USA |